{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1235.350","meta":{"versionId":"6","lastUpdated":"2023-08-08T01:00:54.000-04:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"B.well Connected Health Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2023-08-08"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2023-08-08"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1235.350"}],"version":"20230808","name":"COVID19Vaccine_EventClinicalGrouping","title":"COVID19 Vaccine_Event Clinical Grouping","status":"active","date":"2023-08-08T01:00:54-04:00","publisher":"B.well Connected Health Steward","description":"b.well created value set by Sr. Clinical Business Analyst for the COVID19 Vaccine_Event Clinical Grouping.","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Data Element Scope: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Inclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.),(Exclusion Criteria: This value set's intent is to define the clinical codes that constitute the COVID19 Vaccine_Event Clinical Grouping and utilization in patients/users connected health.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348"]},{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349"]}]},"expansion":{"identifier":"urn:uuid:1ff79f86-a2d4-45ec-aad5-5bf905bab85f","timestamp":"2023-12-11T00:29:14-05:00","total":74,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0001A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0002A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0003A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0004A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0011A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0012A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0013A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0031A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0034A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0041A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0042A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0051A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0052A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0053A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; third dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0054A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0064A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0071A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0072A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0073A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; third dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0074A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0081A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0082A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0083A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, third dose (6 months through 4 years)"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0091A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; first dose, when administered to individuals 6 through 11 years"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0092A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; second dose, when administered to individuals 6 through 11 years"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0093A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sarscov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 50 mcg/0.5 ml dosage; third dose, when administered to individuals 6 through 11 years"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0094A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0111A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0112A","display":"Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0113A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, preservative free, 25 mcg/0.25 ml dosage; third dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0124A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, tris-sucrose formulation, booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0144A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrnalnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, booster dose"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"0154A","display":"Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, booster dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"207","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"208","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"210","display":"SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mL"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"211","display":"SARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"212","display":"SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"217","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"218","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"219","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 3 mcg/0.2mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"221","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"227","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 50 mcg/0.5 mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"228","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"229","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 50 mcg/0.5 mL or 25 mcg/0.25 mL dose"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"230","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2468235","display":"SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2470234","display":"SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 0.2 MG/ML Injectable Suspension"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"2479835","display":"SARS-COV-2 (COVID-19) vaccine, vector - Ad26 100000000000 UNT/ML Injectable Suspension"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"300","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 30 mcg/0.3 mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"301","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 10 mcg/0.2 mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"302","display":"SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent, preservative free, 3 mcg/0.2 mL dose, tris-sucrose formulation"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"502","display":"SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"506","display":"SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"510","display":"SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"511","display":"SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"518","display":"SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"519","display":"SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna"},{"system":"http://hl7.org/fhir/sid/cvx","version":"20231102","code":"520","display":"SARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTech"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91300","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91301","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91303","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use"},{"system":"http://www.ama-assn.org/go/cpt","version":"2024","code":"91304","display":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91304","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91305","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91306","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91307","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91308","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91309","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91311","display":"Severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91312","display":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, trissucrose formulation, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91313","display":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 50 mcg/0.5 ml dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91314","display":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, for intramuscular use"},{"system":"http://www.nlm.nih.gov/research/umls/hcpcs","version":"2023","code":"91315","display":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) vaccine, mrna-lnp, bivalent spike protein, preservative free, 10 mcg/0.2 ml dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use"}]}}